Thisobservation highlights the necessity of accurately quantifying TfR1levels within tumors to guide patient selection and optimize treatmentstrategies. Immunohistochemistry (IHC)is widely regarded as the clinical benchmark for measuring TfR1 expressionin tumor specimens. The gene discussed is TFRC; the disease is neoplasm.